ISAL 2019 | What we still don’t know about the RATIFY study of midostaurin in AML

Richard Stone

The Phase III RATIFY study (NCT00651261) investigated daunorubicin, cytarabine and the FLT3 inhibitor midostaurin for the treatment of newly diagnosed acute myeloid leukemia (AML). Here, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the questions remaining from this trial, speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Share this video